Nektar's Drug Shows Promise in Asthma & Eczema
Update: 2025-11-10
Description
Nektar Therapeutics experimental drug, rezpegaldesleukin, showed promising results in improving asthma symptoms for patients with atopic dermatitis. The drug led to significant improvements in asthma control scores after sixteen weeks, with 75% of patients on the highest dose experiencing a clinically important improvement. The study, called REZOLVE-AD, is in its second phase and is expected to provide more long-term data in the first quarter of 2026. Nektar also plans to release data for this drug in treating alopecia areata in December 2025.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
